XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53
2020 · Journal of Hematology & Oncology · 52 citations
https://doi.org/10.1186/s13045-020-00982-3
B
Benjamin M. Parsons
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
252
Papers
4.6K
Citations
27
h-index
41
i10-index
Benjamin M. Parsons is an academic researcher from Gundersen Health System. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Lymphoma Diagnosis and Treatment & Radiomics and Machine Learning in Medical Imaging. The author has an h-index of 27, co-authored 215 publications.
ORCID: 0000-0002-5634-2937Papers by this author
worksDevelopment and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit
2023 · Communications Medicine · 29 citations
https://doi.org/10.1038/s43856-023-00243-7
A US Registry–Based Assessment of Use and Impact of Chemotherapy in Stage I HER2-Positive Breast Cancer
2018 · Journal of the National Comprehensive Cancer Network · 17 citations
https://doi.org/10.6004/jnccn.2018.7058
Multicenter Analysis of Elderly Hodgkin Lymphoma (eHL): Outcomes and Prognostic Factors in the Modern Era
2011 · Blood · 1 citations
https://doi.org/10.1182/blood.v118.21.2625.2625
Prognostic gene expression and microRNA profiling signatures and genetic alterations in primary testicular diffuse large B-cell lymphoma
2025 · Research Square · 0 citations
https://doi.org/10.21203/rs.3.rs-5732026/v1
Prognostic gene expression and microRNA profiling signatures and genetic alterations in primary testicular diffuse large B-cell lymphoma
2025 · Blood Cancer Journal · 0 citations
https://doi.org/10.1038/s41408-025-01323-8
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat